Cargando…
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria
BACKGROUND: Chloroquine has been recommended for Plasmodium vivax infections for >60 years, but resistance is increasing. To guide future therapies, the cumulative benefits of using slowly eliminated (chloroquine) vs rapidly eliminated (artesunate) antimalarials, and the risks and benefits of add...
Autores principales: | Chu, Cindy S, Phyo, Aung Pyae, Lwin, Khin Maung, Win, Htun Htun, San, Thida, Aung, Aye Aye, Raksapraidee, Rattanaporn, Carrara, Verena I, Bancone, Germana, Watson, James, Moore, Kerryn A, Wiladphaingern, Jacher, Proux, Stéphane, Sriprawat, Kanlaya, Winterberg, Markus, Cheah, Phaik Yeong, Chue, Amy L, Tarning, Joel, Imwong, Mallika, Nosten, François, White, Nicholas J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206118/ https://www.ncbi.nlm.nih.gov/pubmed/29889239 http://dx.doi.org/10.1093/cid/ciy319 |
Ejemplares similares
-
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria
por: Chu, Cindy S, et al.
Publicado: (2019) -
Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens
por: Chu, Cindy S., et al.
Publicado: (2017) -
Dihydroartemisinin-Piperaquine Versus Chloroquine in the Treatment of Plasmodium vivax Malaria in Thailand: A Randomized Controlled Trial
por: Phyo, Aung Pyae, et al.
Publicado: (2011) -
Chloroquine–Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial
por: Awab, Ghulam Rahim, et al.
Publicado: (2017) -
Transplant Programs in APBMT: Blood and Marrow Transplant Activity Report from Myanmar
APBMT Meeting 2018, Taiwan
por: Gyi, Aye Aye, et al.
Publicado: (2019)